Use of hydroxocobalamin to treat intraoperative vasoplegic syndrome refractory to vasopressors and methylene blue during liver transplantation

Sher Lu Pai, Klaus D. Torp, Vianca C. Insignares, Samuel DeMaria, Chris R. Giordano, Ilana I. Logvinov, Zhuo Li, Ryan Chadha, Stephen Aniskevich

Research output: Contribution to journalArticlepeer-review

Abstract

Introduction: For patients with catecholamine-resistant vasoplegic syndrome (VS) during liver transplantation (LT), treatment with methylene blue (MB) and/or hydroxocobalamin (B12) has been an acceptable therapy. However, data on the effectiveness of B12 is limited to case reports and case series. Methods: We retrospectively reviewed records of patients undergoing LT from January 2016 through March 2022. We identified patients with VS treated with vasopressors and MB, and abstracted hemodynamic parameters, vasopressor requirements, and B12 administration from the records. The primary aim was to describe the treatment efficacy of B12 for VS refractory to vasopressors and MB, measured as no vasopressor requirement at the conclusion of the surgery. Results: One hundred one patients received intraoperative VS treatment. For the 35 (34.7%) patients with successful VS treatment, 14 received MB only and 21 received both MB and B12. Of the 21 patients with VS resolution after receiving both MB and B12, 17 (89.5%) showed immediate, but transient, hemodynamic improvements at the time of MB administration and later showed sustained response to B12. Conclusion: Immediate but transient hemodynamic response to MB in VS patients during LT supports the diagnosis of VS and should prompt B12 administration for sustained treatment response.

Original languageEnglish
Article numbere15271
JournalClinical Transplantation
Volume38
Issue number3
DOIs
StatePublished - Mar 2024

Keywords

  • cardiovascular disease
  • hydroxocobalamin
  • liver transplantation
  • methylene blue
  • vasoplegia
  • vasoplegic syndrome

Fingerprint

Dive into the research topics of 'Use of hydroxocobalamin to treat intraoperative vasoplegic syndrome refractory to vasopressors and methylene blue during liver transplantation'. Together they form a unique fingerprint.

Cite this